Evidence map›Paper›PMID 37974278›Full record

ArticleCell communication and signaling : CCS2023

Simvastatin induces pyroptosis via ROS/caspase-1/GSDMD pathway in colon cancer.

Wei Xie, Mingjing Peng, Ying Liu, Bocheng Zhang, Liang Yi, Ying Long

Open access · goldAbstract readVideo-Audio Media
In one paragraph

Article in Cell communication and signaling : CCS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
11.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. The gasdermin family: from pyroptosis mechanisms to therapeutic targets.Signal transduction and targeted therapy · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Caspase-1 in cancer and inflammatory diseases: a potential therapeutic target.Apoptosis : an international journal on programmed cell death · 2026
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. 27-Hydroxycholesterol in cancer development and drug resistance.Journal of enzyme inhibition and medicinal chemistry · 2025
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Wei Xie *Translational medicine centre, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, Hunan, P. R. China.
Mingjing Peng *Central laboratory, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, P. R. China.
Ying Liu *Hunan Provincial Clinical Research Centre for Oncoplastic Surgery, Hunan Cancer hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, Hunan, 410013, P. R. China.
Bocheng ZhangTranslational medicine centre, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, Hunan, P. R. China.
Liang YiHunan Provincial Clinical Research Centre for Oncoplastic Surgery, Hunan Cancer hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, Hunan, 410013, P. R. China.
Ying LongTranslational medicine centre, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, Hunan, P. R. China. longying@hnca.org.cn.
Hunan Cancer Hospital · CNCentral South University · CN

Funding

Hunan Provincial Science and Technology Department 2018SK2123National Natural Science Foundation of China 81703005Natural Science Foundation of Hunan Province 2022JJ40255Natural Science Foundation of Hunan Province 2021JJ40328Natural Science Foundation of Hunan Province 2023JJ60120Science and Technology Bureau, Changsha kq2014209
6 · The paper itself

Abstract

backgroundThe outcome of patients with colon cancer is still unsatisfied nowadays. Simvastatin is a type of statins with anti-cancer activity, but its effect on colon cancer cells remains unclear. The present study is intended to determine the underlying mechanism of simvastatin in treatment of colon cancer.

methodsThe viability and pyroptosis rate of cells treated and untreated with simvastatin were analysed by CCK-8 and flow cytometry assays, respectively. We used DCFH-DA and flow cytometry to detect reactive oxygen species (ROS) production. Levels of pyroptosis markers were detected by western blotting analysis or immunofluorescence staining. Besides, the anticancer properties of simvastatin on colon cancer were further demonstrated using a cell line based xenograft tumor model.

resultsSimvastatin treatment in HCT116 and SW620 induced pyroptosis and suppressed cell proliferation, with changes in the expression level of NLPR3, ASC, cleaved-caspase-1, mature IL-1β, IL-18 and GSDMD-N. Moreover, inhibition of caspase-1 and ROS attenuated the effects of simvastatin on cancer cell viability. In addition, it was identified that simvastatin has an anti-tumor effect by down-regulating ROS production and inducing downstream caspase-1 dependent pyroptosis in the subcutaneous transplantation tumors of HCT116 cells in BALB/c nude mice.

conclusionsOur in vitro and in vivo results indicated that simvastatin induced pyroptosis through ROS/caspase-1/GSDMD pathway, thereby serving as a potential agent for colon cancer treatment. Video Abstract.

Indexed as

Colonic NeoplasmsPyroptosisAnimalsCaspase 1Disease Models, AnimalGasderminsHCT116 CellsHumansMiceMice, NudePhosphate-Binding ProteinsPore Forming Cytotoxic ProteinsReactive Oxygen SpeciesSimvastatinCaspase 1GasderminsGSDMD protein, humanPhosphate-Binding ProteinsPore Forming Cytotoxic ProteinsReactive Oxygen SpeciesSimvastatinCaspase-1Colon cancerPyroptosisROSSimvastatin

Identifiers

PMID37974278
PMCPMC10652480
OpenAlexW4388733926

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.